Agenda - Obesity Science & Innovation EU | Obesity Science & Innovation Europe (OSI EU)

08:00 - 08:30

Registration

Showing 1 of 1 Streams

Opening Keynote Plenary

08:30 - 08:40

Obesity Science & Innovation Europe Welcome

Kaitlin Dailey - Senior Conference Producer, Informa Connect

08:40 - 08:45

Chair

08:45 - 09:15

Keynote Presentation: Decoding The Future of Obesity Care: The Signals Worth Paying Attention To

Ekaterina Grinko - Business Innovation & Partnerships Lead Obesity & GLP-1, Novo Nordisk

09:15 - 10:05

Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape

Annagret Van Der Aaa - CEO, Cantoni Therapeutics
Ekaterina Grinko - Business Innovation & Partnerships Lead Obesity & GLP-1, Novo Nordisk
Steffen-Sebastian Bolz - CSO, Aphaia Pharma
Saleha Patel - Head of Pipeline and Commercialization Strategy, Constructive Bio

10:05 - 10:35

Morning Break

Showing 1 of 1 Streams

Clinical & Translational Updates

10:35 - 10:40

Chair

10:40 - 11:05

Presentation: Exploring A Selective Amylin Receptor Agonist for Metabolic Disease

Gabe Smolarz - VP Medical Affairs, Zealand Pharma

11:05 - 11:25

The Obesity Multi-Omic Atlas: Driving Target Discovery

Large Human Obesity Cohort: Integrates multi-tissue samples (liver, adipose, muscle, intestine) with rich clinical data from 2,000 bariatric surgery patients
High-Resolution Discovery: Applies bulk, single-cell, single-nuclei, and spatial omics to uncover novel, human-validated therapeutic targets
Patient Stratification: Enables molecular patient segmentation to identify specific obesity endotypes and mechanistic drivers

Jeremie Boucher - SVP, Head of Metabolic Disease, Evotec

11:25 - 11:50

Presentation: Genetically-Validated INHBE Silencing with SLN098 siRNA for Enhanced Fat Loss and Lean Mass Preservation

Lucas Bethge - VP, Group Leader Chemistry, Silence Therapeutics

11:50 - 12:15

Presentation: Energy Expenditure Modulation as an Emerging Therapeutic Strategy for Obesity

Martin Hey-Mogensen - Scientific Director, Emerging Obesity Mechanism, The Energy Expenditure Group, Novo Nordisk

12:15 - 13:25

Lunch Break

Showing 1 of 1 Streams

Technology and Process Innovation Spotlight

13:25 - 13:30

Chair

13:30 - 13:50

Presentation: Engineering Advanced GLP-1 Peptides Through Targeted Site-Specific Modifications

Robert Salmon - Head of Bioprocess, Constructive Bio

13:50 - 14:10

Presentation: Investigating FKBPL as an Emerging Metabolic Target in Obesity

Stephanie Annett - Senior Lecturer, RCSI

14:10 - 14:30

Presentation: Enteroendocrine Cell Activation via Beaded Oral Glucose: A Multi-Hormonal Approach to Metabolic Regulation

Steffen-Sebastian Bolz - CSO, Aphaia Pharma

14:30 - 14:50

Presentation: Translational Medicine at the Crossroads of Obesity and Type 2 Diabetes: From Disease Mechanisms to Precision Therapeutics

Farhad Rezaee - Principle Investigator/ Project Leader, Erasmus Medical Center Rotterdam

14:50 - 15:10

Presentation: First-in-Class Small Molecule Targeting Adipocyte Futile Cycling for Weight Loss

Joanne Hsieh - Head of Metabolism, Gordian Biotechnology

15:10 - 15:40

Afternoon Break

Showing 1 of 1 Streams

Afternoon Keynote Plenary

15:40 - 16:05

Keynote Presentation: The Missing Signal in Obesity Care: Turning Everyday Patient Data into Better Clinical Conversations

Marcelo Duhalde - CGO, smartpatient

16:05 - 16:30

Keynote Presentation: Weight A Minute - The Patient Perspective

Natasja Wijling - Board Member & Patient Advocate, Dutch Association for Overweight & Obesity (NVOO)

16:30 - 16:35

Closing Remarks

Kaitlin Dailey - Senior Conference Producer, Informa Connect

16:35 - 16:40

Close of OSI Europe 2026

Informa helps businesses and professionals in hundreds of ways.

Obesity Science & Innovation EUFriday, 6 November 2026 - UTC +1